Surgery pp 2087-2095 | Cite as

Gastrointestinal Stromal Tumors

  • Jason S. Gold
  • Ronald P. DeMatteo


Despite its relative rarity as a clinical entity, gastrointestinal stromal tumor (GIST) has garnered much interest in the past several years. The recognition of KIT activation as essential in the tumorigenesis of GIST and the subsequent treatment of GISTs with a molecular inhibitor of KIT signaling, imatinib mesylate (STI 571, Gleevec; Novartis Pharmaceuticals, Basel, Switzerland), represent landmark achievements in solid tumor oncology. The use of imatinib in the management of GIST most likely signals the beginning of the application of specific molecular and genetic approaches to cancer therapy. Thus, the integration of surgery and targeted therapy in the treatment of GIST, which is currently the subject of much investigation, may serve as a paradigm for the multimodality management of other solid malignancies.


Chronic Myeloid Leukemia Stromal Tumor National Comprehensive Cancer Network Gastrointestinal Stromal Tumor National Comprehensive Cancer Network 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kindblom LG. Gastrointestinal stromal tumors: diagnosis, epidemiology, prognosis. Presented at ASCO Annual Meeting, Chicago, IL, 2003.Google Scholar
  2. 2.
    Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer (Phila) 1995;75:154–170.PubMedCrossRefGoogle Scholar
  3. 3.
    DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–58.PubMedCrossRefGoogle Scholar
  4. 4.
    Pierie J-PEN, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383–389.PubMedCrossRefGoogle Scholar
  5. 5.
    Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898–3905.PubMedCrossRefGoogle Scholar
  6. 6.
    Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003;6:39–48.PubMedCrossRefGoogle Scholar
  7. 7.
    Langer C, Gunawan B, Schuler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003;90:332–339.PubMedCrossRefGoogle Scholar
  8. 8.
    Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999;23:82–87.PubMedCrossRefGoogle Scholar
  9. 9.
    DeMatteo RP, Maki RG, Antonescu CC, Brennan MF. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg 2003;40:144–193.PubMedCrossRefGoogle Scholar
  10. 10.
    Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459–465.PubMedCrossRefGoogle Scholar
  11. 11.
    Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 1998;279:577–580.PubMedCrossRefGoogle Scholar
  12. 12.
    Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 2004;10:3282–3290.PubMedCrossRefGoogle Scholar
  13. 13.
    Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–4349.PubMedCrossRefGoogle Scholar
  14. 14.
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996;2:561–566.PubMedCrossRefGoogle Scholar
  15. 15.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–1042.PubMedCrossRefGoogle Scholar
  16. 16.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.PubMedCrossRefGoogle Scholar
  17. 17.
    Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054–5058.PubMedCrossRefGoogle Scholar
  18. 18.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052–1056.PubMedCrossRefGoogle Scholar
  19. 19.
    Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708–710.PubMedCrossRefGoogle Scholar
  20. 20.
    Fletcher JA, Corless CL, Dimitrijevic S, et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2003;22:815.Google Scholar
  21. 21.
    Demetri GD, Desai J, Fletcher JA, et al. SU11248, a multi-targeted tryosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 2004;22(14S):3001.Google Scholar
  22. 22.
    Desai J, Maki R, Heinrich MC, et al. Activity and tolerability of the multitargeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Presented at 2004 Gastrointestinal Cancers Symposium, San Francisco, CA, 2004.Google Scholar
  23. 23.
    DeMatteo RP, Heinrich MC, El-Rifai WeM, Demetri G. Clinical management of gastrointestinal stromal tumors. Hum Pathol 2002;33:466–477.PubMedCrossRefGoogle Scholar
  24. 24.
    Berthet B, Sugarbaker TA, Chang D, Sugarbaker PH. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 1999;35:413–419.PubMedCrossRefGoogle Scholar
  25. 25.
    Eilber FC, Rosen G, Forscher C, et al. Recurrent gastrointestinal stromal sarcomas. Surg Oncol 2000;9:71–75.PubMedCrossRefGoogle Scholar
  26. 26.
    Eilber FC, Rosen G, Forscher C, et al. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999;6:645–650.PubMedCrossRefGoogle Scholar
  27. 27.
    Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001;8:50–59.PubMedCrossRefGoogle Scholar
  28. 28.
    Miettinen M, El-Rifai WeM, Leslie HS, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478–483.PubMedCrossRefGoogle Scholar
  29. 29.
    Demetri GD, Benjamin R, Blanke CD, et al. Optimal management of patients with gastrointestinal stromal tumors (GIST): expansion and update of NCCN Clinical Practice Guidelines. J Comprehensive Cancer Network 2004;(in press).Google Scholar
  30. 30.
    DeMatteo RP, Shah A, Fong Y, et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001;234:540–547; discussion 547–548.PubMedCrossRefGoogle Scholar
  31. 31.
    van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421–1423.PubMedCrossRefGoogle Scholar
  32. 32.
    Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484–495.PubMedCrossRefGoogle Scholar
  33. 33.
    van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38:S83–S87.PubMedCrossRefGoogle Scholar
  34. 34.
    Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 2003;22:814.Google Scholar
  35. 35.
    Verweij PJ, Casali PG, Zalcberg PJ, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet 2004;364:1127–1134.PubMedCrossRefGoogle Scholar
  36. 36.
    Blanke C, Joensuu H, Demetri G, et al. Long-term follow-up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Presented at 2004 Gastrointestinal Cancers Symposium, San Francisco, CA, 2004.Google Scholar
  37. 37.
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–480.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jason S. Gold
    • 1
    • 2
  • Ronald P. DeMatteo
    • 3
    • 4
    • 5
  1. 1.Surgical Service VA Boston Healthcare System, West Roxbury MAHarvard Medical SchoolBostonUSA
  2. 2.Department of Surgery, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  3. 3.Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  4. 4.Division of General Surgical OncologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  5. 5.General Surgical Oncology Fellowship ProgramMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations